Publique un comentario 
COVID-19: Importancia de la resistencia a la insulina en la respuesta a la terapia antiviral con interferón
Resumen
Referencias
Würtz P, Wang Q, Kangas AJ, Richmond RC, Skarp J, Tiainen M, et al. Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med. 2014;11(12): e1001765. DOI: 10.1371/journal.pmed.1001765
Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10.
Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al: Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-96. DOI: 10.1016/S0140-6736(09)60318-4
Global burden of metabolic risk factors for chronic diseases collaboration (BMI Mediated Effects), Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB et al: Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet. 2014;383(9921):970-83. DOI: 10.1016/S0140-6736(13)61836-X
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation. 2014;129(25 Suppl 2):S102-S138. DOI: 10.1161/01.cir.0000437739.71477.ee
Burgio E, Lopomo A, Migliore L. Obesity and diabetes: from genetics to epigenetics. Mol Biol Rep. 2015;42:799-818.
Adolfi C, Fisichella PM. Epidemiology of obesity and associated comorbidities. J Laparoendosc Adv Surg Tech A. 2018;28(8):919-24.
Kelishadi R, Roufarshbaf M, Soheili S, Payghambarzadeh F, Masiedi M. Association of childhood obesity and the immune system: A systematic review of reviews. Child Obes. 2017;13(4): 332-46.
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamet A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020 [acceso: 09/04/2020]. 28:1195-9 Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.22831
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clinical Immunology. 2020;215:108448. DOI: https://doi.org/10.1016/j.clim.2020.108448
Bain VG, Kaita KD, Marotta P, Yoshida EM, Swain MG, Bailey RJ, et al. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastro Hep. 2008;6:701-6.
Grasso A, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. Journal of Hepatology. 2009;51:984-90.
Ryan P, Resino S, Miralles P, Cosin J, Lopez JC, Moreno S, et al. Insulin resistance impairs response to interferon plus ribavirin in patients coinfeted with HIV and Hepatitis C virus. J Acquir Immune Defic Syndr. 2010;55:176-81.
Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon /ribavirin combination tholerapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105:1970-7.
Vachon MLC, Factor SH, Branch AD, Fiel MI, Rodríguez-Torres M, Brau N, et al. Insulin resistance predicts retreatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV coinfected patients. J Hepatol. 2011;54(1): 41-7.
Del Campo JA, Aparcero R, Romero-Gomez M. Insulin resistance and response to antiviral therapy in chronic hepatitis C: Mechanisms and Management. Dig Dis. 2010;28:285-93.
Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khatta MA, et al. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther. 2011;34:297-305.
Hee Jae J, Young Seok K, Sang Gyune K, Yun Nah L, Soung Won J, Jae Young J, et al. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clinical and Molecular Hepatology. 2014;20:38-46.
Wang X, Zhao YR, Liu HL, Ma XH, Zhan Y, Yi RT. Insulin resistance predicts virological response to interferon-α in chronic hepatitis B patients. J Clin Gastroenterology. 2016,50(6):506-12.
Sreejjth Vasudevan S, Amit Kavimandan NK, Baibaswata Nayak BT, Prasenjit D, Siddhartha Datta G, Subrat Kumar P. Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India. Indian J Med Res. 2016;143(3): 331-40.
Todorovska B, Joksimovic N, Caloska-Ivanova V, Dimitrova-Genadieva M, Trajkovska M, Curakova E, et al. Factors that influence the virological response in patients with chronic hepatitis C treated with pegylated interferón and ribavirin. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017;38(1):25-33.
Perich Amador P, González Suárez RM, Valdés Ramos E, Arranz Calzado MC. Desarrollo de diabetes mellitus en pacientes con tolerancia a la glucosa alterada: Seguimiento de 18 años. Rev Cubana Endocrinol. 2002 [acceso: 16/05/2020]; 13(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532002000200002&lng=es
Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Endocrinol Metab Clin N Am. 2008;37:581-601.
Cabrera Rode E, Rodríguez Camerón V, Rodríguez J, Cubas Dueñas I, Álvarez Álvarez A, Arnold Domínguez Y, et al. Evaluación de tres metodologías para la predicción del riesgo de alteraciones del metabolismo de la glucosa en sujetos con sobrepeso y obesidad. Rev Cubana Endocrinol. 2017 [acceso: 16/05/2020]; 28(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532017000200003&lng=es
Chan KV, Wong VT, Tang SCV. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese –Western Medicine for the Management of 2019 Novel Coronavirus Disease. Am. J. Chin. Med. 2020;48:737-62.
Prada DM, Rosabal N, Molinero C, Gómez JA, Hernández IM, López AM, et al. Artritis Reumatoide: beneficios clínicos observados en pacientes tratados con anticuerpo monoclonal Itolizumab. (T1h mAB), 2 años después de recibir tratamiento. Revista Cubana de Reumatología 2011 [acceso: 16/05/2020]; 13(17). Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/30
Enlaces refback
- No hay ningún enlace refback.
Copyright (c) 2020 Eduardo Cabrera Rode, Ileana Cubas Dueñas, Oscar Díaz Díaz
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
La revista está: Certificada por el CITMA
La revista es de acceso abierto y gratuito.